Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Chinese Medicine
  4. Vol 6, Issue 3, 2024

Research progress in the combined treatment of traditional Chinese and Western medicine for myasthenia gravis

Download as PDF

DOI: 10.23977/medcm.2024.060320 | Downloads: 16 | Views: 672

Author(s)

Wenfeng Chen 1

Affiliation(s)

1 First Clinical College of Integrative Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei, 430000, China

Corresponding Author

Wenfeng Chen

ABSTRACT

Myasthenia gravis (MG) is a common neurological disease and one of the incurable diseases to date. With the development of medical technology this year, there have been more treatment methods. This article reviews the progress in the treatment of MG with Western medicine and the combination of Chinese and Western medicine in recent years.

KEYWORDS

Myasthenia gravis, modern medicine, Integrated Traditional Chinese and Western Medicine, Treatment progress

CITE THIS PAPER

Wenfeng Chen, Research progress in the combined treatment of traditional Chinese and Western medicine for myasthenia gravis. MEDS Chinese Medicine (2024) Vol. 6: 142-148. DOI: http://dx.doi.org/10.23977/medcm.2024.060320.

REFERENCES

[1] Feng Xia. Progress in the treatment of myasthenia gravis[J]. Chinese Medical Guide, 2014, 9(11): 911.
[2] Yang Mingshan, Fang Siyu, Ruan Xuzhong. Diagnosis and treatment of neurological emergencies[M]. Wuhan: Hubei Science and Technology Press, 1995: 403-416.
[3] Fan Weinu, Hong Wenke. Observation of the efficacy of cyclophosphamide or azathioprine in steroid-resistant myasthenia gravis [J]. Modern Practical Medicine, 2009, 21(5): 463-465.
[4] Xiong Xiaoping, Yu Feng, Wang Weiqiang, et al. Clinical observation of high-dose cyclophosphamide intermittent pulse therapy for generalized myasthenia gravis[J]. Shandong Medical Journal, 2009, 49(44): 92-93.
[5] Li Xiuhua, Cheng Yan, Yang Li, et al. The effect of immunosuppressants on T lymphocyte subsets in myasthenia gravis patients [J]. Chinese Journal of Practical Neurological Diseases, 2008, 11(5): 1-4.
[6] Hu Qing, Jiang Haiwei, Ge Lintong, et al. Clinical observation of mycophenolate mofetil in the treatment of 28 cases of myasthenia gravis[J]. Clinical Internal Medicine Journal, 2014, 31(6): 407-409.
[7] Dong Mengqi, Guo Junhong, Zhang Jin. Management of refractory myasthenia gravis[J]. International Journal of Immunology, 2017, 40(2): 216-220.
[8] Kerty E, Elsais A, Argov Z, et al. EFNS/ENS guidelines for the treatment of ocular myasthenia[J]. Eur J Neurol, 2014, 21(5): 687-693.
[9] Wang Ke, Xu Peng, Zhang Ying, et al. Comparison and analysis of domestic and foreign guidelines for the treatment of myasthenia gravis [J]. Journal of Practical Medicine, 2022, 38(08): 917-922.
[10] Sanders D B, Wolfe G I, Benatar M, et al. International consensus guidance for the management of myasthenia gravis: Executive summary[J]. Neurology, 2016, 87(4): 419-425.
[11] Beecher G, Anderson D, Siddiqi Z A. Rituximab in refractory myasthenia gravis: Extended prospective study results [J]. Muscle Nerve, 2018, 58(3): 452-455.
[12] Hehir M K, Hobson-Webb L D, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: Multi-center blinded prospective review [J]. Neurology, 2017, 89: 10-100.
[13] Rother R P, Rollins S A, Mojcik C F, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria[J]. Nat Biotechnol, 2007, 25(11): 1256-1264.
[14] Howard J F Jr, Barohn R J, Cutter G R, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis [J]. Muscle Nerve, 2013, 48(1): 76-84.
[15] Howard J F Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): A phase 3, randomized, double-blind, placebo-controlled, multicenter study[J]. Lancet Neurol, 2017, 16(12): 976-986.
[16] Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis [J]. Muscle Nerve, 2019, 60(1): 14-24.
[17] He Lifeng, Shen Shuang, Yang Xiangyan, et al. Surgical treatment of 45 cases of myasthenia gravis with thymic abnormalities[J]. Journal of Practical Medicine, 2021, 37(7): 962-964.
[18] Gong Taiqian, Jiang Yaoguang, Wang Ruwen. The immunological mechanism of thymectomy in the treatment of myasthenia gravis [J]. Journal of Immunology, 2002, 18(z1): 221-223.
[19] Wolfe G I, Kaminski H J, Aban I B, et al. Randomized trial of thymectomy in myasthenia gravis[J]. N Engl J Med, 2016, 375(6): 511-522.
[20] Liu Z, Feng H, Yeung S C, et al. Extended transcervical thymectomy for the treatment of ocular myasthenia gravis[J]. Ann Thorac Surg, 2011, 92(6): 1993-1999.
[21] Zhu K, Li J X, Huang X, et al. Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: A systematic review and meta-analysis [J]. Neurol Sci, 2017, 38(10): 1753-1760.
[22] Shrager J B, Nathan D, Brinster C J, et al. Outcomes after 151 extended transcervical thymectomies for myasthenia gravis [J]. Ann Thorac Surg, 2006, 82(5): 1863-1869.
[23] Mineo T C, Ambrogi V. Outcomes after thymectomy in class I myasthenia gravis[J]. Thorac Cardiovasc Surg, 2015, 145(5): 1319-1324.
[24] Fan Zhiming, Wen Guoqiang, Zhang Zhenhe. The value of thymectomy in the treatment of myasthenia gravis[J]. Chinese Medical Journal, 1998, 78(5): 363-365.
[25] Luo Weiting. Observation of the efficacy of high-dose intravenous immunoglobulin in severe myasthenia gravis[J]. Contemporary Medicine, 2012, 18(19): 11-13.
[26] Wilf-Yarkoni A, Lotan I, Steiner I, et al. Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis [J]. J Neurol, 2021, 268(10): 3871-3877.
[27] He Guoliang, Wu Keqing, Ye Yun, Cai Donghui. Advances in the understanding of myasthenia gravis and treatment strategies [J]. Chinese Journal of Neurology, 2016, 49(6): 371-376.
[28] Chen Hui, Huang Yu, Chen Chao, et al. The application of stem cell therapy in myasthenia gravis[J]. Chinese Journal of Practical Neurology, 2018, 21(4): 325-329.
[29] Wang Y, Liu Y, Zhang Z, et al. Advances in research on the pathogenesis of myasthenia gravis[J]. Journal of Clinical Neuroscience, 2015, 22(3): 479-483.
[30] Ma Jianhua, Zhang Jianzhong. Myasthenia gravis in children: Clinical characteristics and treatment strategies[J]. Chinese Journal of Pediatrics, 2019, 57(4): 272-277.
[31] Li Xin, Wu Xin, Li Shuguang. The relationship between thyroid disease and myasthenia gravis[J]. Journal of Clinical Endocrinology and Metabolism, 2014, 30(12): 1303-1308.
[32] Zhang Yi, Wang Shaohua. An analysis of risk factors for myasthenia gravis and its complications[J]. Journal of Modern Medicine, 2020, 28(1): 105-110.
[33] Wang Jianjun, Zhan Jun. The impact of psychological factors on the quality of life of patients with myasthenia gravis [J]. Chinese Journal of Psychological Medicine, 2017, 50(4): 281-285.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 8494
Visits: 470868

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.